A wireless, wearable sensor detected fevers due to infection and cytokine release syndrome (CRS) several hours earlier than did standard temperature monitoring, according to research published in Cancer Cell.

Researchers tested the sensor, called TempTraq, in a prospective study of 62 patients with cancer who were receiving hematopoietic stem cell transplants (HSCTs, 39 patients) or chimeric antigen receptor (CAR) T-cell therapy (23 patients).

TempTraq is applied as an axillary skin patch. It captures high-frequency temperature measurements every 2 minutes and transmits the data in real-time to a cloud-based server. The sensor is approved by the US Food and Drug Administration.

Continue Reading

Researchers compared the sensor’s measurements to standard temperature measurements, which are typically taken every 4 to 8 hours as part of routine clinical care in the hospital.

Overall, the sensor detected fevers a median of 4.9 hours earlier than did standard care. The sensor detected 24 of 27 fevers (89%) a median of 5.5 hours earlier. The 3 fevers detected earlier by standard care were identified a median of 1.9 hours earlier.

The sensor detected infection-related fevers significantly earlier than CRS-related fevers, at a median of 18.5 hours and 4.4 hours earlier than standard care, respectively (P =.012).

The researchers also found they could detect “subtle perturbations” in the sensor data that predicted fevers about 3.5 hours before they occurred.

Based on these results, the researchers concluded that the sensor can provide “considerable lead time” for the early detection of febrile adverse events, and this lead time is “clinically significant for patients with cancer.”

Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.


Flora C, Tyler J, Mayer C, et al. High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer. Cancer Cell. 2021;39(9):1167-1168. doi:10.1016/j.ccell.2021.07.019

This article originally appeared on Cancer Therapy Advisor